Sherman Morris
Department of Medicine, University Health Network, Toronto, Canada.
Semin Liver Dis. 2005;25(2):143-54. doi: 10.1055/s-2005-871194.
In this article, the epidemiology of hepatocellular carcinoma (HCC), risk factors for the development of HCC, and how these factors affect the decision about whether an individual should or should be entered into a screening program are considered. The factors determining the risk for HCC include age, male gender, and the nature of the underlying liver disease. In particular, cirrhosis is associated with a significant risk for HCC. However, in hepatitis B HCC also occurs in noncirrhotic liver. Decision analysis can be used to identify patients at greatest risk for HCC and who might be candidates for screening. Screening itself should be developed in a programmatic manner to ensure that appropriate target populations are identified, that appropriate screening tests are chosen, and that appropriate recall and enhanced follow-up are instituted for patients who have positive screening test results. Screening should be by ultrasonography at 4- to 12-month intervals. Patients with abnormal screening tests require additional investigation using computed tomography scanning, magnetic resonance imaging, or liver biopsy. Negative results do not exclude the possibility of cancer and further follow-up is necessary.
本文探讨了肝细胞癌(HCC)的流行病学、HCC发生的危险因素,以及这些因素如何影响关于个体是否应纳入筛查计划的决策。决定HCC风险的因素包括年龄、男性性别以及潜在肝脏疾病的性质。特别是,肝硬化与HCC的显著风险相关。然而,在乙型肝炎中,HCC也可发生于非肝硬化肝脏。决策分析可用于识别HCC风险最高且可能适合筛查的患者。筛查本身应以程序化方式开展,以确保确定合适的目标人群、选择合适的筛查试验,并对筛查试验结果呈阳性的患者进行适当的召回和强化随访。筛查应采用超声检查,间隔4至12个月。筛查试验异常的患者需要使用计算机断层扫描、磁共振成像或肝活检进行进一步检查。阴性结果并不排除癌症的可能性,有必要进行进一步随访。